Multiplex Deletion of Myeloid Antigens CD33 and CLL-1 by CRISPR/Cas9 in Human Hematopoietic Stem Cells Highlights the Potential of Next-Generation Transplantation for AML Treatment […]
Publication Programs: VOR33-CLL1 + VCAR33-CLL1 Treatment System
Keystone Symposia – 2022 – Poster Presentation 3002
Multiplex Editing of Hematopoietic Stem and Progenitor Cells (HSPCs) with CRISPR Cas Nucleases Achieves High On Target Editing with Undetectable Translocations […]
Read More… from Keystone Symposia – 2022 – Poster Presentation 3002
Keystone Symposia – 2022 – Poster Presentation 3001
Multiplex Base Editing in Human Hematopoietic Stem and Progenitor Cells (HSPCs) Enables Efficient Removal of Multiple Surface Antigens in Acute Myeloid Leukemia (AML) Immunotherapy […]
Read More… from Keystone Symposia – 2022 – Poster Presentation 3001
ASH Annual Meeting 2021 – Poster Presentation 2939
Multiplex Engineering of Human CD34+ HSPCs Enables Dual Gene Knockout While Maintaining High Engraftment Potential and Safety […]
Read More… from ASH Annual Meeting 2021 – Poster Presentation 2939